Original Article| Volume 23, ISSUE 6, P1351-1355, July 2014

Proposed Approach to Thrombolysis in Dabigatran-Treated Patients Presenting with Ischemic Stroke


      Acute ischemic stroke thrombolysis in patients taking dabigatran is controversial because of a presumed increased risk of symptomatic hemorrhagic transformation. Using data from our local hematopathology laboratory, we developed a thrombolysis protocol for acute ischemic stroke patients taking dabigatran.


      A local thrombin time (TT)–dabigatran concentration relationship was calculated using dabigatran calibrators. The effect of dabigatran on activated partial thromboplastin time (aPTT) and prothrombin time (PT) (international normalized ratio [INR]) was also measured. A protocol was developed, in which a dabigatran concentration less than 10 ng/mL (corresponding to a TT < 38 seconds or a normal aPTT) was selected as the upper limit for thrombolysis. Consecutive patients presenting with acute stroke were then enrolled in this prospective study.


      In the 8 months after development of the protocol, 13 potential thrombolysis candidates taking dabigatran were assessed at a median (interquartile range) time of 192 (143) minutes. The median National Institutes of Health Stroke Scale score was 18 (20). The mean time from arrival to TT, aPTT, and PT (INR) results were 39 ± 4.1 minutes, 21 ± 6.5 minutes, and 21 ± 6.5 minutes, respectively. Based on TT/aPTT, 4 patients were ineligible for thrombolysis. Six patients were not treated because of minor or resolving symptoms and another presented with intracerebral hemorrhage. Two patients were treated with intravenous tissue plasminogen activator (tPA), without symptomatic hemorrhagic transformation in either case. In 3 patients (42.8%), aPTT was normal, despite a prolonged TT.


      Administration of intravenous tPA in dabigatran-treated patients is feasible. Although, the relationship between dabigatran concentrations and coagulation measures varies between laboratories, individual protocols, preferably based on TT, can be developed at acute stroke treatment centers.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kirley K.
        • Qato D.M.
        • Kornfield R.
        • et al.
        National trends in oral anticoagulant use in the United States, 2007 to 2011.
        Circ Cardiovasc Qual Outcomes. 2012; 5: 615-621
        • Ruecker M.
        • Matosevic B.
        • Willeit P.
        • et al.
        Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis.
        Neurology. 2012; 79: 31-38
        • Xian Y.
        • Liang L.
        • Smith E.
        • et al.
        Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
        JAMA. 2012; 307: 2600-2608
        • van Ryn J.
        • Stangier J.
        • Haertter S.
        • et al.
        Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
        Thromb Haemost. 2010; 103: 1116-1127
        • Carr Jr., M.E.
        • Gabriel D.A.
        Hyperfibrinogenemia as a cause of prolonged thrombin clotting time.
        Southern Med J. 1986; 79: 563-570
        • Trouillas P.
        • von Kummer R.
        Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke.
        Stroke. 2006; 37: 556-561
        • Van De Werf F.
        • Brueckmann M.
        • Connolly S.J.
        • et al.
        A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
        Am Heart J. 2012; 163: 931-937.e1
        • O'Donnell M.
        • Oczkowski W.
        • Fang J.
        • et al.
        Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study.
        Lancet Neurol. 2006; 5: 749-754
        • Sangha N.
        • El Khoury R.
        • Misra V.
        • et al.
        Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization.
        J Stroke Cerebrovas Dis. 2012; 21: 917.e5-917.e9
        • Matute M.C.
        • Guillan M.
        • Garcia-Caldentey J.
        • et al.
        Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran.
        Thromb Haemost. 2011; 106: 178-179
        • De Smedt A.
        • De Raedt S.
        • Nieboer K.
        • et al.
        Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran.
        Cerebrovasc Dis. 2010; 30: 533-534
        • Marrone L.C.
        • Marrone A.C.
        Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report.
        Cerebrovasc Dis. 2012; 34: 246-247
        • Lee V.H.
        • Conners J.J.
        • Prabhakaran S.
        Intravenous thrombolysis in a stroke patient taking dabigatran.
        J Stroke Cerebrovas Dis. 2012; 21: 916.e11-916.e12
        • Casado Naranjo I.
        • Portilla-Cuenca J.C.
        • Jimenez Caballero P.E.
        • et al.
        Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.
        Cerebrovasc Dis. 2011; 32: 614-615
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        • RE-LY Steering Committee and Investigators
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Rybinnik I.
        • Mullen M.T.
        • Messe S.
        • et al.
        Treatment of acute stroke in patients on dabigatran: A survey of us stroke specialists.
        J Stroke Cerebrovas Dis. 2013; 22: 1312-1316